Recognition of the mortality and morbidity associated with prostate cancer has resulted in einployer based screening programs. This retrospective cohort study identified the employer costs of prostate cancer screening and referrals due to abnormal test results. The subjects were 385 men enrolled in a workplace screening program at a single employer between 1993 and 1995. Screening consisted of digital rectal examination (DRE) annually for enrolled employees aged 40 years and older, plus annual prostate specific antigen (PSA) testing for those 50 and older, and those 40 and older and considered at
high risk. Data related to the health care and lost productivity costs of screening and referrals for abnormal test results were collected and analyzed. The total cost of screening was $44,355, or approximately $56 per screening encounter (788 DREs; 437 PSAs) . Abnormal screening tests resulted in 52 referrals. Upon further evaluation, 42% were found to have an enlargement, 29% a node, and 12% benign prostatic hyperplasia. Only one malignancy was found. The total cost of additional referrals was $31,815, or 42% of the cost of screening plus referrals. As the cost per screening encounter was low, prostate cancer screening in the workplace is an efficient alternative. I n 1996, the American Cancer Society estimated that 317,000 new cases of prostate cancer would occur in the United States that year, with African American men experiencing incidence rates 37% higher than white men. Incidence rates of prostate cancer increased by 65% between 1980 and 1990, mainly because of improved detection . As prostate cancer screening becomes more prevalent, these incidence rates are expected to continue to increase (American Cancer Society, 1996) .
The American Cancer Society (1996) also predicted 41,400 men would die during 1996 as a result of prostate cancer, making it the second leading cause of cancer death in men. African American men experience mortality rates due to prostate cancer twice as high as those for white men. However, survival rates are high if prostate cancer is diagnosed while still localized. The 5 year survival rate for clients with localized disease is 98%. Fiftyseven percent of all prostate cancers are diagnosed while still localized. Survival rates for all stages of prostate cancer have increased from 50% to 85% over the past 30 years (American Cancer Society, 1996) .
Common screening tests for prostate cancer include digital rectal examination (DRE) and prostate specific antigen (PSA) testing. DRE involves examining the symmetry and texture of the prostate to detect lesions. While DRE is the most commonly used prostate cancer screening test, its sensitivity is highly dependent on the skill and experience of the health care professional performing the test. Further, only part of the prostate can be examined by DRE, and the test provides only limited information about tumor size and volume (Waldman, 1994) .
PSA testing can be a more useful test for diagnosing prostate cancer. The test evaluates serum PSA concentrations in the blood, with elevated serum PSA concentrations indicative of prostate cancer. The cut off point for the PSA has been a topic of controversy. A single reference point of 4.0 ng per milliliter has been used. However, age specific cut off points have received attention more recently (Oesterling, 1996) . Further, some argue that the cut off point should be based on both the age and race of the screened subject. Over 40% of prostate cancer cases in African American men would be missed using the traditional cut offs established for white men if specificity were held constant at 95% (Morgan, 1996) . These age specific cut off points assist in making the PSA test more sensitive in younger men and more specific in older men (Oesterling, 1996) .
The American Cancer Society (1994) recommends annual DREs for men 40 years and older and annual PSAs for men 50 years and older or 40 to 49 and at high risk (family or personal history, African American race). One option for implementing these guidelines is for employers to offer on site screening programs for employees as an added health benefit. The cited advantages of implementing an on site prostate cancer screening program include an available and easily monitored population with an established relationship with the company health program, along with the benefits of boosting morale by showing the company cares about its employees (Kantrowitz, 1995) . In addition, on site programs make screening convenient and accessible to employees.
As employers consider implementing programs to screen employees for prostate cancer, they need to be aware of the costs associated with screening. Costs to the employer include those for health care resources associated with screening, along with those associated with employee lost productivity due to screening. Referrals for additional evaluation based on suspicious screening results also can lead to high health care and lost productivity costs, regardless of whether referral results in detection of a malignancy. Therefore, employers should account for the costs of unnecessary referrals due to imperfect specificity of screening tests and to the fact that working age men are at lower risk for prostate cancer than elderly populations.
An analysis was conducted to identify the employer costs of a prostate cancer screening program implemented in the workplace and to identify the costs of referrals 380 based on suspicious findings due to screening. In addition, the costs of a program offering the same services outside of the workplace were estimated to explore whether onsite screening provided added efficiency over screening outside of the workplace.
METHODS

Design
A retrospective cohort study of men enrolled in a workplace prostate cancer screening program was performed to identify the costs for prostate cancer screening and referrals based on suspicious screening findings. Also, the costs of performing the same screening services outside the workplace were estimated.
Setting
Zeneca Pharmaceuticals, Inc. employs approximately 2,260 persons at its United States headquarters in Wilmington, DE. Through its Health Services Medical Department, Zeneca offers screening programs for breast, prostate, and colorectal cancers, as well as general wellness and fitness programs.
The prostate cancer screening program was started in January 1993 to provide employees with screening services and to promote the awareness and understanding of prostate cancer. In 1998, the program continues to operate under the same guidelines. All male employees over the age of 40 years are eligible to participate in the program, offered in the workplace during regular business hours. The program follows the American Cancer Society's prostate screening guidelines for classification of low and high risk populations, as well as the recommended schedule of screening services provided to these two groups (American Cancer Society, 1994).
The American Cancer Society recommends annual DRE for males over the age of 40. Further, annual PSA testing is recommended for males over the age of 50 and men between the ages of 40 to 49 at high risk. Men between the ages of 40 and 49 are considered to be at high risk if they have a family or personal history of prostate cancer or are African American. The other prostate cancer risk factor is dietary fat.
During the time period included in this analysis, screening consisted of a DRE, PSA testing, and employee education. In accordance with the ACS guidelines, DREs were provided annually to all men age 40 and older. Men age 50 and older and those under 50 and considered at high risk for prostate cancer also received an annual PSA.
DREs were performed by a physician employee. Blood samples for the PSAs were drawn by a nurse employee I week prior to the DRE to ensure test results were available at the time the DRE was performed. The blood samples were collected by a local laboratory which performed the PSA. The results of the PSA were usually reported back to the Health Services Medical Department within 24 hours of receiving the sample.
When an abnormal finding on either the PSA or DRE occurred, the employee was referred to his personal health care provider for additional evaluation. Howev-er, men with abnormal results on initial screening could elect to have further testing (PSA and/or DRE) performed on site rather than outside of the workplace.
An abnormal finding on a DRE was defined as a node or enlargement. An abnormal PSA was defined as a serum PSA concentration of greater than 4.0 ng/mL (Fischbach, 1992) . For three men who elected to have additional diagnostic evaluation in the workplace after abnormal screening results, the cost of the additional work-up on site was estimated as equal to initial screening with DRE and PSA ($60) and 1 hour of lost productivity. Using data on the type and quantity of screening services performed in the workplace, the total cost of screening based on using external sources was estimated. It was assumed all men in the workplace program would have been screened outside the workplace using the same testing procedures.
In the analysis of cost of screening outside the workplace, it was assumed each screening encounter entailed an office visit during which the physician performed a DRE. The average cost to the employer of a physician visit during which a DRE is performed, $65, was obtained from the Health Claims Service. This figure was based on services provided by a local urology group practice that submitted claims to the employer during 1993 to 1995. The cost of the PSA test itself, $90, was based on local reasonable and customary charges for this test (personal communication, Zeneca, August 13, 1996) . The cost of the PSA was added to the office visit cost for men who received both a PSA and a DRE.
To determine the cost of lost productivity due to screening outside the workplace, it was assumed that each screening service would require 1.5 hours of missed
Procedures
All men screened between January 1993 and December 1995 were identified, using records maintained for purposes of administering the screening program. From the identified records, data were obtained on the number of DREs and PSAs performed, the number of additional evaluations for suspicious findings on either one of these screenings, and the findings based on additional evaluation, e.g., enlargement, node, benign prostatic hyperplasia (BPH), malignant disease.
The labor, supply, administrative, educational materials, and overhead costs (in 1996 dollars) to the employer for workplace screening services were identified. A summary of these costs is listed in Table 1 . Labor costs for screening consisted of physician and certified occupational health nurse time. Based on the salaries of each of these professionals and the estimated time for each screening service, the professional cost for a DRE was approximately $11 and an additional $20 for a PSA. This included the cost of venipuncture.
The supply cost of the PSA, $18, included the cost of the test itself plus the cost of transferring the blood sample to the laboratory and transmitting the results back to the Health Services Department. The supply cost of DRE was estimated at $1. Administrative costs, including those for tracking client data, maintaining health records, and entering data into a computer, were estimated at $8 per screening encounter (DRE, with or without PSA). Educational costs included distribution of educational materials in the form of pamphlets and videos about prostate cancer and benefits of screening. The materials accounted for $1 per screening encounter. The cost of space (overhead) to operate the screening program within the Health Services Medical Department was approximately $1 per screening encounter.
In addition to determining the employer health care cost of screening, the lost productivity costs to the employer due to missed work for screening also was estimated. It was estimated program participants missed 0.5 hours of work for a DRE and an additional 0.5 hours if they had a PSA. The average hourly wage of these employees was $17 (personal communication, Zeneca Payroll Department, September 19, 1996) .
To obtain the total cost of the screening program, the total number of screening DREs and PSAs was multiplied by the labor, supply, administrative, educational, overhead, and lost productivity cost per screen.
To calculate the health care costs of additional diagnostic evaluations outside of the workplace following abnormal screening, health care services associated with each additional evaluation were identified. Additionally, service specific usual, customary, and reasonable charges work, including travel, waiting, and screening. Therefore, the lost productivity analysis included 1.5 hours of missed work for men receiving only a DRE and 3.0 hours of missed work for men receiving both a DRE and a PSA. Table 2 summarizes the costs of prostate cancer screening on site versus outside of the workplace. Screening outside of the workplace was assumed to produce results identical to actual results obtained through the workplace program. Further evaluation of suspicious findings due to screening outside the workplace was assumed to be the same as actual follow up evaluations obtained by the men participating in the workplace program. Therefore, no on site versus offsite comparisons were made for the number of referrals or for follow up evaluations.
Analysis
The total cost of the screening program and the total cost of referrals for additional diagnostic evaluation due to suspicious findings from screening were calculated using resource utilization data and associated costs. Furthermore, cost differences between screening provided in the workplace and external source screening were estimated.
RESULTS
From 1993 through 1995, 385 men participated in the prostate cancer screening program. Men aged 40 to 49 and not at high risk comprised 43% (146 of 343) of those screened in 1993, 52% (108 of 209) in 1994, and 41% (97 of 236) in 1995. During this period, 788 DREs and 437 PSAs were performed. The costs of screening are presented in Table 3 .
Fifty-two men had an abnormal finding on the screening DRE, PSA, or both; 6 (12%) were men aged 40 -49 and not at high risk, in whom the abnormal finding was enlargement based on DRE alone. Of the 46 abnormal findings among men aged 50 or older, or < 50 and at 382 'Costs reported are in 1996 dollars. tlncludes physician and nurse labor for ORE and PSA screening. §Includes PSA test, gloves, and hemoccult test. high risk, 17 (37%) were abnormal DRE alone, 9 (20%) were abnormalPSA alone, and 20 (43%) were both abnormal DRE and abnormal PSA. Ninety-four percent (49) of individuals with an abnormal finding elected to obtain additional diagnostic evaluation outside of the workplace, while the remaining three received additional evaluation in the workplace. The additional workplace evaluation consisted of follow up DRE and/or PSA performed on site, with no further evaluation with external sources. Data on the diagnostic status following additional evaluation are shown in the Figure. Of those receiving additional evaluation, 22 (42%) had enlargement, 15 (29%) had a node, and 6 (12%) had BPH. One malignancy was detected.
Resources and costs for additional evaluation due to abnormal screening are shown in Table 4 . The total cost of screening (Table 3 ) and additional evaluation combined was $76,170. Therefore, the cost of referrals amounted to almost 42% of the total cost, including direct and lost productivity costs.
For comparison, the costs of screening with external sources were estimated. The costs of performing the same screening services outside the workplace were $121,788, including screening costs of $90,550 and lost productivity costs of $31,238. These same costs for screening in the workplace total $44,355, approximately 36% of the costs for off site screening. The estimated average cost per external screening encounter is $155, 277% of the average cost of screening in the workplace.
DISCUSSION
Using historical data from a single employer, the health care and lost productivity costs of a prostate cancer screening program implemented in the workplace, the costs of additional evaluation due to abnormal findings on screening, and the costs of off site comparable screening services were estimated. Study findings indicated the employer cost per screening encounter, $56, is quite low. Comparison to the estimated cost per off site screening encounter, $155, suggests that prostate cancer screening was performed cost efficiently when performed in the workplace. The referral rate per screening encounter (DRE alone or DRE plus PSA) was approximately 7% (52 referrals and 788 encounters). However, only one of the additional evaluations following a suspicious screening finding resulted in detection of malignant disease. Also, six cases of BPH were detected. No cases of BPH or malignant disease were found among screened men under age 50 and not at high risk.
Several limitations of the analysis should be mentioned. The potential savings realized by an employer through early detection of disease were not taken into account nor were the potential health benefits of early detection. Routine screening increases the probability of detecting disease and increases the proportion of localized disease at diagnosis. Therefore, routine screening has the potential to improve survival. Men with localized disease have lO year survival rates of 75%, while men with regional extension have survival rates of only 55%. The same survival rate drops to 15% in men with distant metastases (Kramer, 1993) .
Another issue associated with implementing a prostate cancer screening program for a population of working men is that about 80% of prostate cancers are diagnosed in men over age 65. Because men in the working population are likely to be under 65, one might ques- AUGUST 1998, VOL. 46, NO.8 tion whether an employer based screening program targets the men in most need of screening. However, some evidence suggests prostate cancers that occur in younger men are more aggressive and, therefore, more important to detect early (Berger, 1993) . If this is the case, an employer based screening program could be important in detecting these more aggressive cancers.
Further, potential cost savings are associated with early detection. If sufficient numbers of malignancies are detected earlier than would have happened without screening, savings due to early detection could offset some of the costs of the program itself. However, it is not clear whether malignancies detected at early stages are less expensive to manage than those detected at late stages. In this program, screening resulted in detection of only one malignancy and six cases of BPH. Therefore, savings are likely to have been small. Also, analyses of other types of screening programs suggest it is unlikely that costs of screening can be entirely offset by these savings. A study of mammographic screening in the workplace found that the total lifetime cost of treating early stage breast cancer may be greater than treating late stage cancer because of improved survival of early stage individuals (Griffiths, 1996) . Nevertheless, this type of screening is cost effective because the expenditure required to save a year of life through early detection of breast cancer is low compared to other types of health services for which employers commonly pay.
Prostate cancer screening has comparatively low overhead costs because there is no capital equipment to purchase and maintain. However, it is likely some minimum number of enrollees is required to make screening in the workplace more cost efficient than screening outside the workplace. That is, while fixed costs are low for prostate cancer screening in the workplace, a minimum amount of participation is required to make on site screening more efficient than sending employees off site for screening. Without sufficient employee participation, the costs for a physician employee to administer screening could exceed the costs of sending employees to external screening sources. The minimum number of enrollees required to make screening in the workplace more efficient than screening outside the workplace was not addressed in this analysis. Also, in estimating the costs of screening outside the workplace, it was assumed screening would require a separate health care provider visit. Had it been assumed that screening took place during a regularly scheduled check up, the marginal cost of screening outside the workplace (health care and lost productivity) could have been significantly lower.
The analysis also did not address the non-financial costs associated with screening. Screening can cause anxiety, particularly related to false positive results. In this study 52 men had abnormal findings referred for further follow up. Of these 52 men, one man had prostate cancer. Therefore, 51 men had false positive screening results that may have caused them considerable anxiety. Additionally, the follow up testing, including biopsies for nine men, potentially involved discomfort. Two men with benign disease underwent transurethral resection of the
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What Does This Mean?
Health care professionals considering implementing prostate cancer screening programs in the workplace need to consider costs associated with such a program. These costs include the costs associated with screening, the costs of referrals for abnormal findings, and the lost productivity associated with screening.
The findings from this analysis suggest that costs of prostate cancer screening in the workplace are low. However, the costs of unnecessary referrals for abnormal screening results may substantially increase the costs of screening itself. When considering implementation of a prostate cancer screening program for employees, both the screening costs and the costs due to follow up evaluations of abnormal screening results merit attention.
Aside from the economic implications, a workplace based screening program provides employees with a convenient option for obtaining prostate cancer screening. This convenience could promote use of screening services for men who might not otherwise seek out screening. Finally, offering on site screening as an added benefit shows gOOdwill on the part of the employer. prostate (TURP), which can have side effects such as impotence and incontinence. Therefore, when considering implementation of a prostate cancer screening program, non-financial costs associated with screening also must be included.
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